Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Victoria, Soldatenkova"'
Autor:
Brian A Van Tine MD, PhD, Anders Krarup-Hansen MD, PhD, Lisa M Hess PhD, Albiruni R Abdul Razak MD, Victoria Soldatenkova MSc, Jennifer Wright MD, Se Hoon Park MD
Publikováno v:
Rare Tumors, Vol 14 (2022)
Background: Patient-reported outcomes (PROs), including health-related quality of life, are recommended to be routinely collected in clinical trials, but data are limited from trials of sarcoma patients. In this analysis, pooled PRO data are reported
Externí odkaz:
https://doaj.org/article/eeb8b1752f264cfaa1ea44fc9c3eb400
Autor:
Vivek, Subbiah, Jürgen, Wolf, Bhavana, Konda, Hyunseok, Kang, Alexander, Spira, Jared, Weiss, Masayuki, Takeda, Yuichiro, Ohe, Saad, Khan, Kadoaki, Ohashi, Victoria, Soldatenkova, Sylwia, Szymczak, Loretta, Sullivan, Jennifer, Wright, Alexander, Drilon
Publikováno v:
The Lancet Oncology. 23:1261-1273
Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions occur rarely in other tumour types. We aimed to investigate the efficacy a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc3c5a7ba9e08650e6904334833fb7d4
https://doi.org/10.1016/s1470-2045(22)00541-1
https://doi.org/10.1016/s1470-2045(22)00541-1
Autor:
Alexander Drilon, Vivek Subbiah, Oliver Gautschi, Pascale Tomasini, Filippo de Braud, Benjamin J. Solomon, Daniel Shao-Weng Tan, Guzmán Alonso, Jürgen Wolf, Keunchil Park, Koichi Goto, Victoria Soldatenkova, Sylwia Szymczak, Scott S. Barker, Tarun Puri, Aimee Bence Lin, Herbert Loong, Benjamin Besse
Publikováno v:
Scientia
Selpercatinib; Lung cancer; Safety Selpercatinib; Cáncer de pulmón; Seguridad Selpercatinib; Càncer de pulmó; Seguretat PURPOSE Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase inhibitor, is currently approved f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7234be8c79bdb581bfe91eff1f129bac
https://hdl.handle.net/11351/9323
https://hdl.handle.net/11351/9323
Autor:
Alexander, Drilon, Vivek, Subbiah, Oliver, Gautschi, Pascale, Tomasini, Filippo, de Braud, Benjamin J, Solomon, Daniel, Shao-Weng Tan, Guzmán, Alonso, Jürgen, Wolf, Keunchil, Park, Koichi, Goto, Victoria, Soldatenkova, Sylwia, Szymczak, Scott S, Barker, Tarun, Puri, Aimee, Bence Lin, Herbert, Loong, Benjamin, Besse
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 41(2)
Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase inhibitor, is currently approved for the treatment of patients withPatients were enrolled to LIBRETTO-001, a phase I/II, single-arm, open-label study of selpercatinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::765195bda1dd85cefc6dfb87f1c727c7
https://pubmed.ncbi.nlm.nih.gov/36207414
https://pubmed.ncbi.nlm.nih.gov/36207414
Autor:
Hannah M Davis, Jürgen Wolf, Keunchil Park, Boris Lin, Herbert H. Loong, Benjamin Solomon, Maurice Pérol, Fernando C. Santini, Victoria Soldatenkova, Alexander Drilon, Silvia Novello, Edurne Arriola, Koichi Goto, Aimee Bence Lin, C. Zhou, Yasir Elamin, Andreas Sashegyi
Publikováno v:
Future Oncology. 17:763-773
Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell lung cancer patients in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1a14d0a19297afb403fa300a7dce7d6
https://doi.org/10.2217/fon-2020-0935
https://doi.org/10.2217/fon-2020-0935
Autor:
Caroline E. McCoach, Christian Rolfo, Alexander Drilon, Mario Lacouture, Benjamin Besse, Koichi Goto, Viola W. Zhu, Daniel S.W. Tan, Stephanie Farajian, Laura A. Potter, Jennifer F. Kherani, Victoria Soldatenkova, Elizabeth A. Olek, Catherine E. Muehlenbein, Keunchil Park
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 17(6)
Immune checkpoint inhibitor (ICI) therapy has been found to increase the risk/severity of immune-mediated adverse events with subsequent kinase inhibitor treatment in oncogenically driven cancers. We explored the risk for hypersensitivity with selper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a5363d47a4e5efb60ede931e3096a1b
https://pubmed.ncbi.nlm.nih.gov/35623671
https://pubmed.ncbi.nlm.nih.gov/35623671
Autor:
Vivek Subbiah, Juergen Wolf, Bhavana Konda, Hyunseok Kang, Alexander I. Spira, Jared Weiss, Masayuki Takeda, Yuichiro Ohe, Saad A. Khan, Kadoaki Ohashi, Victoria Soldatenkova, Sylwia Szymczak, Loretta Sullivan, Jennifer Wright, Alexander E. Drilon
Publikováno v:
Journal of Clinical Oncology. 40:3094-3094
3094 Background: Selpercatinib, a first-in-class highly selective and potent RET kinase inhibitor, is approved in multiple countries for the treatment of lung and thyroid cancer with RET fusions and medullary thyroid cancer with RET mutations. We pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::23587115a3db75f28971e2802c53c66b
https://doi.org/10.1200/jco.2022.40.16_suppl.3094
https://doi.org/10.1200/jco.2022.40.16_suppl.3094
Autor:
Peter Driesen, Marc Lambrechts, Kees Kraaij, Victoria Soldatenkova, Nadia Chouaki, Benoit Colinet
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 5 (2013)
Objectives: The aim of this study was to evaluate the efficacy and tolerability of the combination of cisplatin–gemcitabine with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC). Methods: This was a phase
Externí odkaz:
https://doaj.org/article/f479eedee3da4742a6f53a27506bae08
Autor:
Akira Kawai, Brian A. Van Tine, Javier Martin-Broto, Andrew J. Wagner, Albiruni Ryan Abdul Razak, Se Hoon Park, Yoichi Naito, Robin L. Jones, Patrick Schöffski, Jennifer Wright, William D. Tap, Chueh Chuan Yen, Victoria Soldatenkova, Axel Le Cesne, Ashwin Shahir, Gary Mo, Alexander I. Spira, Zsuzsanna Papai, Anders Krarup-Hansen, Kristen N. Ganjoo, Alexander Fedenko
Publikováno v:
JAMA
IMPORTANCE: Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival benefit in this population was observed with the addition of olaratumab to doxorubicin over doxo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25085751de5c8c86f2c24b8627fe7121
https://pubmed.ncbi.nlm.nih.gov/32259216
https://pubmed.ncbi.nlm.nih.gov/32259216
Autor:
A. Drilon, C. Zhou, A. Bence Lin, Juergen Wolf, Boris Lin, Ben Solomon, Fernando C. Santini, E. Arriola Aperribay, Maurice Pérol, Yasir Elamin, Victoria Soldatenkova, Koichi Goto, Andreas Sashegyi, K. Park, Silvia Novello, Herbert H. Loong
Publikováno v:
Journal of Thoracic Oncology. 16:S228-S229
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9aa0e09a060b1d4bcb4fdcd743ae291f
https://doi.org/10.1016/j.jtho.2021.01.148
https://doi.org/10.1016/j.jtho.2021.01.148